[go: up one dir, main page]

MX2016012667A - Composiciones y metodos relacionados con el diagnostico de cancer de prostata. - Google Patents

Composiciones y metodos relacionados con el diagnostico de cancer de prostata.

Info

Publication number
MX2016012667A
MX2016012667A MX2016012667A MX2016012667A MX2016012667A MX 2016012667 A MX2016012667 A MX 2016012667A MX 2016012667 A MX2016012667 A MX 2016012667A MX 2016012667 A MX2016012667 A MX 2016012667A MX 2016012667 A MX2016012667 A MX 2016012667A
Authority
MX
Mexico
Prior art keywords
prostate cancer
diagnosis
compositions
methods related
aspects
Prior art date
Application number
MX2016012667A
Other languages
English (en)
Other versions
MX392384B (es
Inventor
Vincent Linder
David Steinmiller
j vickers Andrew
T Scardino Peter
Pettersson Kim
Lovgren Timo
Lilja Hans
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of MX2016012667A publication Critical patent/MX2016012667A/es
Publication of MX392384B publication Critical patent/MX392384B/es

Links

Classifications

    • G01N33/57555—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)

Abstract

Aspectos de la divulgación se refieren a métodos mejorados para predecir si una biopsia de tejido de próstata obtenida de un sujeto contendrá cáncer de próstata detectable.
MX2016012667A 2014-03-28 2015-03-27 Composiciones y metodos relacionados con el diagnostico de cancer de prostata. MX392384B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (2)

Publication Number Publication Date
MX2016012667A true MX2016012667A (es) 2017-01-09
MX392384B MX392384B (es) 2025-03-24

Family

ID=54196462

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012667A MX392384B (es) 2014-03-28 2015-03-27 Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
MX2022002365A MX2022002365A (es) 2014-03-28 2016-09-27 Composiciones y metodos relacionados con el diagnostico de cancer de prostata.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022002365A MX2022002365A (es) 2014-03-28 2016-09-27 Composiciones y metodos relacionados con el diagnostico de cancer de prostata.

Country Status (24)

Country Link
US (2) US11761962B2 (es)
EP (2) EP3123381B1 (es)
JP (3) JP6775488B2 (es)
KR (1) KR102505543B1 (es)
CN (2) CN114740202A (es)
AR (1) AR099883A1 (es)
AU (1) AU2015237270B2 (es)
CA (1) CA2944001C (es)
CL (1) CL2016002419A1 (es)
DE (1) DE202015009668U1 (es)
DK (1) DK3123381T3 (es)
EA (1) EA201691952A1 (es)
ES (1) ES2964706T3 (es)
FI (1) FI3123381T3 (es)
HU (1) HUE065029T2 (es)
IL (2) IL247981B (es)
MX (2) MX392384B (es)
MY (1) MY192513A (es)
PE (1) PE20170298A1 (es)
PL (1) PL3123381T3 (es)
PT (1) PT3123381T (es)
SG (2) SG11201608035UA (es)
TW (1) TWI687688B (es)
WO (1) WO2015148979A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
PE20150333A1 (es) 2012-03-05 2015-03-25 Arctic Partners Ab Oy Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
UA124522C2 (uk) 2015-03-27 2021-10-05 Опко Дайегностікс, Елелсі Спосіб кількісної оцінки рівнів простатичного антигену
KR102783861B1 (ko) * 2015-10-05 2025-03-21 프레닥스 에이비 인간화 항 psa(5a10) 항체
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
PL3397387T3 (pl) 2015-12-29 2021-11-22 Opko Diagnostics, Llc Urządzenie do zbierania płynów i związane z nim metody
JP2020507838A (ja) * 2017-01-08 2020-03-12 ザ ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド 対象特有の肺炎転記を予測するための教師付き学習を使用するためのシステムおよび方法
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
EP4407631A3 (en) 2019-10-11 2024-10-09 C The Signs Limited Diagnostic tool
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514B (zh) * 2024-08-08 2024-10-29 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
CA2175056A1 (en) 1993-10-28 1995-05-04 Imants R. Lauks Fluid sample collection and introduction device
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
KR19990036069A (ko) 1995-08-03 1999-05-25 이.에이치. 리링크 진단 장치
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
EP1151142A2 (en) 1999-01-28 2001-11-07 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
AU2001297014A1 (en) 2000-10-10 2002-04-22 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
CA2428011A1 (en) 2000-11-20 2002-06-13 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
US20040219163A1 (en) 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
JP4191608B2 (ja) 2001-12-05 2008-12-03 ユニヴァーシティ オブ ワシントン 固相アフィニティー結合アッセイのための、微小流体デバイスおよび表面修飾プロセス
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003242389A1 (en) 2002-05-28 2003-12-12 Jokoh Co., Ltd Immunological chromatograph method test slip reading/quantitative determination device
ES2346202T3 (es) 2002-08-06 2010-10-13 The Johns Hopkins University Uso de biomarcadores para detectar cancer.
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
WO2005056186A1 (en) 2003-12-10 2005-06-23 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
US7736890B2 (en) 2003-12-31 2010-06-15 President And Fellows Of Harvard College Assay device and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
DK1776181T3 (da) 2004-01-26 2014-01-06 Harvard College System og fremgangsmåde til fluidtilførsel
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP1747466A2 (en) 2004-05-11 2007-01-31 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
CA2575641A1 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
AU2005287074A1 (en) 2004-09-17 2006-03-30 Ciphergen Biosystems, Inc. Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122310A2 (en) 2005-05-11 2006-11-16 The Trustess Of The University Of Pennsylvania System for testing
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
AU2007231487B2 (en) 2006-03-24 2014-01-09 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
WO2008003656A2 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
US9182400B2 (en) 2006-12-22 2015-11-10 Phadia Ab Prostate kallikrein allergen
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
WO2008140774A2 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
US20110039284A1 (en) 2007-10-22 2011-02-17 Samuel Norbert Breit Methods of prognosis
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
EP2281201B1 (en) 2008-05-14 2018-03-28 ETH Zurich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
EP4016105A1 (en) 2008-10-20 2022-06-22 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer program for generating same
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
US20100168621A1 (en) 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
NZ596054A (en) 2009-05-01 2013-07-26 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
DE112010002253T5 (de) * 2009-06-04 2013-01-03 Charité - Universitätsmedizin Berlin Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
US8932523B2 (en) 2010-04-16 2015-01-13 Opko Diagnostics, Llc Systems and devices for analysis of samples
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
KR101968485B1 (ko) 2011-07-21 2019-04-12 후지필름 와코 준야꾸 가부시키가이샤 혈장중 아미노산 분석용 표준액
RU2606773C2 (ru) 2011-10-28 2017-01-10 Фредакс Аб Терапевтические средства и их применение
WO2013106778A2 (en) 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
PE20150333A1 (es) 2012-03-05 2015-03-25 Arctic Partners Ab Oy Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
MX360236B (es) 2012-06-27 2018-10-26 Berg Llc Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
AU2013349721B2 (en) 2012-11-20 2019-03-28 A3P Biomedical Ab Prognostic method for individuals with prostate cancer
EP2922967B1 (en) 2012-11-20 2018-01-03 Phadia AB Method for indicating a presence or non-presence of aggressive prostate cancer
IL297678B2 (en) 2013-11-19 2024-09-01 Fredax Ab Humanised anti kallikrein-2 antibody
AU2015230017B2 (en) 2014-03-11 2021-06-17 A3P Biomedical Ab Method for detecting a solid tumor cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US10217619B2 (en) 2015-03-12 2019-02-26 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed intact protein analytes
UA124522C2 (uk) 2015-03-27 2021-10-05 Опко Дайегностікс, Елелсі Спосіб кількісної оцінки рівнів простатичного антигену
CN107530412A (zh) 2015-04-29 2018-01-02 欧普科诊断有限责任公司 用于主动监控前列腺癌的组合物和方法
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
WO2019221930A1 (en) 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
AU2015237270B2 (en) 2021-09-09
KR20170008729A (ko) 2017-01-24
CA2944001A1 (en) 2015-10-01
MX392384B (es) 2025-03-24
CA2944001C (en) 2023-08-15
IL280039A (en) 2021-03-01
FI3123381T3 (fi) 2023-11-27
JP2021009157A (ja) 2021-01-28
IL247981B (en) 2021-02-28
JP2023017841A (ja) 2023-02-07
CL2016002419A1 (es) 2017-03-31
KR102505543B1 (ko) 2023-03-02
CN114740202A (zh) 2022-07-12
WO2015148979A8 (en) 2016-01-07
WO2015148979A1 (en) 2015-10-01
HUE065029T2 (hu) 2024-04-28
SG11201608035UA (en) 2016-10-28
CN106663149A (zh) 2017-05-10
EA201691952A1 (ru) 2017-05-31
PT3123381T (pt) 2023-12-22
AR099883A1 (es) 2016-08-24
DE202015009668U1 (de) 2019-01-21
US20230393137A1 (en) 2023-12-07
AU2015237270A1 (en) 2016-10-20
PL3123381T3 (pl) 2024-02-26
MX2022002365A (es) 2022-04-06
IL247981A0 (en) 2016-11-30
IL280039B (en) 2021-12-01
DK3123381T3 (da) 2023-11-27
EP3299977A1 (en) 2018-03-28
EP3123381B1 (en) 2023-10-11
EP3123381A4 (en) 2018-02-21
JP2017515127A (ja) 2017-06-08
ES2964706T3 (es) 2024-04-09
US20160025732A1 (en) 2016-01-28
JP7256781B2 (ja) 2023-04-12
SG10201808585TA (en) 2018-11-29
US11761962B2 (en) 2023-09-19
PE20170298A1 (es) 2017-04-18
MY192513A (en) 2022-08-24
JP6775488B2 (ja) 2020-10-28
BR112016022407A2 (pt) 2017-12-12
JP7506131B2 (ja) 2024-06-25
EP3123381A1 (en) 2017-02-01
TWI687688B (zh) 2020-03-11
TW201621320A (zh) 2016-06-16

Similar Documents

Publication Publication Date Title
MX2016012667A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
TW201613648A (en) Compounds and compositions for immunotherapy
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
PT3110336T (pt) Conjunto de agulha de biopsia
ECSP17015977A (es) Terapia de combinacion
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX392040B (es) Estandares de antigeno prostatico y sus usos.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
PT3170005T (pt) Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
SG11201606106SA (en) Specific biomarker set for non-invasive diagnosis of liver cancer
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3178404A4 (en) Ultrasonic biopsy needle
EP3178406A4 (en) Ultrasonic biopsy needle
PT3229830T (pt) Métodos de tratamento e prognóstico de tumores malignantes não hematopoieticos
TH1501005132A (th) องค์ประกอบ และวิธีการสำหรับการวินิจฉัย และการรักษามะเร็งตับ